Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager obrixtamig (BI 764532) in Patients with DLL3-Positive Tumors: Patients with LCNEC - Wermke, M; Saalfeld, F; Gambardella, V; Kuboki, Y; Olatunji, A; Morgensztern, D; Sayehli, C; Sanmamed, M Miguel F.; Arriola, E; Wolf, J; Liza Villaruz, L; Studeny, M; Bouzaggou, M; Fang, X; Felip, E (Pneumologie, 2025)